Ketim Therapeutics Appoints Dr Carrie Hillyard to Board of Directors

Brisbane, Australia – 14/01/2025 Ketim Therapeutics (Ketim Therapeutics Pty Ltd), a leader in developing innovative biomarker-driven solutions for perinatal mental health, is pleased to announce the appointment of Dr Carrie Hillyard AM to its Board of Directors.

Dr Carrie Hillyard AM BSc PhD FTSE FAICD FQA is an experienced director with a life sciences industry background. She is a mentor to start-up companies and young scientists seeking careers with industry.  She currently chairs the Mater Research Advisory Board and Fitgenes Australia Ltd and is a Director of AAMRI. She is also a patron on AngelLoop which equips entrepreneurs with the vital early-stage business acumen required to enable new and exciting Innovations to succeed and be carried through to reach the market through commecialisation.

After a career spanning medical research on bone, calcium metabolism and cancer in London to inventing, patenting and developing diagnostics in Brisbane, she co-founded venture capital firm, CM Capital Investments, where she built and led the Life Sciences practice, taking an active rôle on the boards of pharmaceutical, diagnostics and medical device investee companies. CMCI raised and managed over $260M in three funds directed at life sciences and telecommunications technologies. Two funds attracted Institutional and international investors.

Carrie has been a member of several Federal and State government boards and advisory bodies, providing advice on the development of the biotechnology and venture capital industries, and has also served on not-for-profit and university commercialisation company boards.

Passionate about assisting young women to achieve their life and career goals, Carrie mentors those looking for industry connections or to redirect their careers into industry. She is involved in the start-up ecosystem in Brisbane and beyond and mentors founders and entrepreneurs developing their ideas. She has been appointed as Patron for Angel Loop.

In recognition of her contributions to biotechnology, she has received awards from AusBiotech and Women in Technology and a Centenary medal. She was elected to the Fellowship of the Academy of Technological Sciences and Engineering in 1997 and recently served on its board for 6 years. She was made a Member of the Order of Australia in 2019.

Commenting on the appointment, Dr Clarissa Yates, Founder and CEO of Ketim Therapeutics, said:
"Dr Hillyard’s unparalleled expertise and leadership in life sciences and commercialisation will be instrumental in guiding Ketim’s growth as we transition from discovery to clinical utility. We are honoured to welcome her to our board."

This appointment reflects Ketim’s commitment to advancing its mission to transform maternal mental health care through innovative biomarker screening and personalised therapeutics.

For media inquiries, please contact:

Dr. Clarissa Yates
CEO, Ketim Therapeutics
Email: clarissa.yates@ketim.com.au